Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The update appears to be a minor version bump from v3.4.1 to v3.4.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T02:40:20.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T22:33:43.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Added a glossary to the page and updated QC-related labels, including 'Last Update Submitted that Met QC Criteria' and the revision note 'Revision: v3.4.0'; removed the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the previous revision 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-28T20:02:13.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-14T03:49:33.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations section now lists Oregon as a study site, reflected in Revision: v3.3.3. The previous Oregon Locations and HHS Vulnerability Disclosure links were removed (v3.3.2).
    Difference
    0.2%
    Check dated 2025-12-23T22:00:56.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Added explicit PSA progression criteria (a ≥25% increase and ≥2 ng/mL above nadir, confirmed ≥3 weeks later) and a plan to plot Kaplan-Meier progression-free survival curves by subgroup, together with an updated estimated study completion date of 2026-06-30.
    Difference
    0.4%
    Check dated 2025-12-09T19:14:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.